Back to top
more

WAVE Life Sciences (WVE)

(Delayed Data from NSDQ)

$4.74 USD

4.74
397,715

-0.27 (-5.39%)

Updated Apr 25, 2024 03:59 PM ET

After-Market: $4.76 +0.02 (0.42%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

F Value F Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Balance Sheet

Research for WVE

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

 

Fiscal Year End for WAVE Life Sciences Ltd falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 200 89 151 185 147
Receivables 21 0 0 30 20
Notes Receivable 0 0 0 0 0
Inventories 0 0 0 0 0
Other Current Assets 14 10 12 16 18
Total Current Assets 235 99 163 230 185
Net Property & Equipment 13 17 22 29 36
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 30
Deferred Charges 0 0 0 0 0
Intangibles 0 0 0 0 0
Deposits & Other Assets 4 4 4 4 14
Total Assets 275 146 207 279 284
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 0 0 0 0
Accounts Payable 13 17 7 14 9
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 0 0 0 0 0
Accrued Expenses 17 18 15 12 16
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 150 32 37 92 90
Total Current Liabilities 186 72 64 121 118
Mortgages 0 0 0 0 0
Deferred Taxes/Income 16 80 77 41 63
Convertible Debt 0 0 0 0 0
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 0 0 0 0 0
Other Non-Current Liabilities 0 0 0 0 2
Minority Interest (Liabilities) 8 8 8 8 8
Total Liabilities 235 191 175 196 221
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 935 803 750 694 540
Capital Surplus 129 119 88 72 57
Retained Earnings -1,025 -967 -806 -683 -533
Other Equity 0 0 0 0 0
Treasury Stock 0 0 0 0 0
Total Shareholder's Equity 40 -45 33 83 64
Total Liabilities & Shareholder's Equity 275 146 207 279 284
Total Common Equity 40 -45 33 83 64
Shares Outstanding 99.00 86.90 58.80 48.70 34.20
Book Value Per Share 0.40 -0.52 0.55 1.70 1.86

Fiscal Year End for WAVE Life Sciences Ltd falls in the month of December.

All items in Millions except Per Share data.

3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Assets          
Cash & Equivalents -99,999 200 140 173 208
Receivables NA 21 7 0 0
Notes Receivable NA 0 0 0 0
Inventories NA 0 0 0 0
Other Current Assets NA 14 12 12 12
Total Current Assets NA 235 159 185 220
Net Property & Equipment NA 13 14 15 16
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 0 0 0 0
Deposits & Other Assets NA 4 4 5 6
Total Assets NA 275 200 230 267
Liabilities & Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 13 13 12 12
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 0 0 0 0
Accrued Expenses NA 17 13 10 8
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 150 68 111 107
Total Current Liabilities NA 186 100 140 133
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 16 105 105 131
Convertible Debt NA 0 0 0 0
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 0 0 0 0
Other Non-Current Liabilities NA 0 0 0
Minority Interest (Liabilities) NA 8 8 8 8
Total Liabilities NA 235 240 282 302
Shareholders Equity 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 935 841 840 838
Capital Surplus NA 129 127 125 122
Retained Earnings NA -1,025 -1,009 -1,016 -995
Other Equity NA 0 0 0 0
Treasury Stock NA 0 0 0 0
Total Shareholder's Equity NA 40 -40 -52 -35
Total Liabilities & Shareholder's Equity NA 275 200 230 267
Total Common Equity 0 40 -40 -52 -35
Shares Outstanding 122.20 99.00 98.90 98.90 98.30
Book Value Per Share 0.00 0.40 -0.41 -0.52 -0.35